Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)

NCT03734991 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

376

Enrollment

INDUSTRY

Sponsor class

Conditions

Candida Vulvovaginitis

Interventions

DRUG: Ibrexafungerp
DRUG: Placebo

Sponsor

Scynexis, Inc.